<DOC>
	<DOCNO>NCT01137552</DOCNO>
	<brief_summary>This first human , open-label , sequential dose escalation expansion study AMG 780 62 subject advance solid tumor . The dose escalation part study aim evaluate safety , tolerability , pharmacokinetics pharmacodynamics AMG 780 . The dose expansion consist 20 subject dose level AMG 780 dependent upon emerge safety PK data dose escalation part study .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study AMG 780 Adult Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Men woman ≥ 18 year old Must pathologically document , definitely diagnose , advance solid tumor refractory standard treatment , curative therapy available , subject refuse standard therapy Measurable disease RECIST criterion Must able undergo MRI evaluation Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Competent sign date Institutional Review Board approve inform consent form Presence untreated symptomatic primary central nervous system tumor metastases Presence leukemia myelodysplastic syndrome Subjects head neck cancer Previous hematopoietic stem cell transplant ( allogeneic ) Unresolved hematological toxicity &gt; grade 1 exception grade 2 lymphopenia nonhematological toxicity &gt; grade 1 , exclude alopecia grade 2 neuropathy , prior anticancer therapy Myocardial infarction within 1 year study day 1 , unstable uncontrolled disease/condition relate affect cardiac function History stroke , arterial venous thrombosis , pulmonary embolism within 1 year study Active peripheral vascular disease History bleed diathesis History pulmonary hemorrhage gross hemoptysis within 6 month study Known history adrenal hemorrhage Known positive test human immunodeficiency virus infection , active hepatitis B hepatitis C Major surgery within 1 month study Prior treatment agent target angiopoietinTie2 signal pathway Concurrent antitumor treatment , except Lupron subject prostate cancer selective estrogen receptor modulators ( SERMS ) subject breast cancer , within 4 week ( 6 week nitrosoureas mitomycin ) study day 1 Known sensitivity mammalianderived product , bacteriallyproduced protein , product administer dose Investigational agent within 30 day study Pregnant ( eg , positive urine test ) breastfeeding Subjects childbearing potential , subject partner childbearing potential , use highly effective contraceptive precaution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>First-In-Human</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Dose Expansion</keyword>
	<keyword>Advance Solid Tumors</keyword>
	<keyword>Anti-Angiopoietin</keyword>
	<keyword>Advance Malignancy</keyword>
	<keyword>Cancer</keyword>
	<keyword>Oncology</keyword>
	<keyword>Oncology Patients</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Tumors</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
</DOC>